Asia-Pacific Multiple Myeloma Therapeutics Market by Treatment Type (Chemotherapy (Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)), Targeted Therapy( Proteasome Inhibitor(Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type (Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)), Immunomodulatory Agents(Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Asia-Pacific Multiple Myeloma Therapeutics Market by Treatment Type (Chemotherapy (Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)), Targeted Therapy( Proteasome Inhibitor(Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type (Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)), Immunomodulatory Agents(Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 861 | Pages: 140 | November 2016 | Region: Asia Pacific


The Asia-Pacific Multiple Myeloma Therapeutics Market was worth $1.37 billion in 2016 and estimated to be growing at a CAGR of 5.5%, to reach $1.79 billion by 2021. Due to increase in geriatric population in the countries like China and India, Asia-Pacific is expected to witness highest growth rate in the forecast period.

Multiple myeloma remains comparatively rare, it is a deceptive disease and patients typically deplete treatment alternatives. Myeloma and MGUS are twice as common in blacks paralleled with whites and marginally more common in males than females.

The growth of multiple myeloma therapeutics market will largely be driven by the development of novel therapeutics that have considerably improved clinical outcomes through all stages of the disease, as well as the absence of standard competition in countries like China, Japan and Australia. Evolving multiple myeloma therapies are probable to offer choices in the lapsed or refractory disease setting, in both the second and third lines of treatment, additionally enhancing APAC market growth. High cost associated with treatment of the disease is expected to restrain the market growth.

The Asia-Pacific Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide  (Revlimid), Arsenic trioxide  (Trisenox), Plerixafor  (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.

Based on geography the market is analysed under various regions namely, China, India, Japan, South Korea and Australia. Australia and Japan are most likely to increase in the forecast period due to rising number of myeloma cases in the region.

Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences

                3.3 New Developments

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers

                4.2 Market Restraints

                4.3 Key Challenges

                4.4 Current Opportunities in the Market              

5. Market Segmentation

                5.1 By Treatment Type

                                5.1.1 Chemotherapy

                                                5.1.1.1 Anthracycline antibiotic

                                                5.1.1.2 Alkylating agent

                                5.1.2 Targeted Therapy

                                                5.1.2.1 Proteasome inhibitor

                5.2 By Drug Type                             

                                5.2.1 Corticosteroids      

                                                5.2.1.1 Dexamethasone (Decadron)

                                                5.2.1.2 Prednisone (Deltasone/Orasone)

                                5.2.2 Immunomodulatory agents             

                                                5.2.2.1 Thalidomide (Thalomid)

                                                5.2.2.2 Lenalidomide (Revlimid)

                                                5.2.2.3 Arsenic trioxide (Trisenox)

                                                5.2.2.4 Plerixafor (Mozobil)

6. Geographical Analysis                                              

                6.1 Introduction                               

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                    

                7.3 Molecular Targets in the Pipeline                                      

                7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)

                                7.4.1 Failure Rate            

                                7.4.2 Clinical Trial Duration           

                                7.4.3 Clinical Trial Size    

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 AB Science SA                            

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues             

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 AbbVie Inc.                 

                9.3 Ablynx NV                   

                9.4 Acceleron Pharma Inc.                           

                9.5 IGF Oncology LLC.                    

                9.6 ImmunGene Inc.                      

                9.7 Millennium Pharmaceuticals Inc.                       

                9.8 MimiVax LLC                              

                9.9 Mirna Therapeutics                 

                9.10 RedHill Biopharma Ltd.                        

                9.11 Rhizen Pharmaceuticals S.A.                             

                9.12 Terpenoid Therapeutics Inc.                             

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                      

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Multiple Myeloma Therapeutics Market By Region, From 2016-2021 (USD Billion)
  2. Asia-Pacific Multiple Myeloma Therapeutics Market By Treatment Type, From 2016-2021 (USD Billion)
  3. Asia-Pacific Chemotherapy Market By Region, From 2016-2021 (USD Billion)
  4. Asia-Pacific Targeted Therapy Market By Region, From 2016-2021 (USD Billion)
  5. Asia-Pacific Multiple Myeloma Therapeutics Market By Drug Type, From 2016-2021 (USD Billion)
  6. Asia-Pacific Corticosteroids Market By Region, From 2016-2021 (USD Billion)
  7. Asia-Pacific Immunomodulatory agents Market By Region, From 2016-2021 (USD Billion)
  8. China Multiple Myeloma Therapeutics Market By Treatment Type, From 2016-2021 (USD Billion)
  9. China Multiple Myeloma Therapeutics Market By Drug Type, From 2016-2021 (USD Billion)
  10. India Multiple Myeloma Therapeutics Market By Treatment Type, From 2016-2021 (USD Billion)
  11. India Multiple Myeloma Therapeutics Market By Drug Type, From 2016-2021 (USD Billion)
  12. Japan Multiple Myeloma Therapeutics Market By Treatment Type, From 2016-2021 (USD Billion)
  13. Japan Multiple Myeloma Therapeutics Market By Drug Type, From 2016-2021 (USD Billion)
  14. South Korea Multiple Myeloma Therapeutics Market By Treatment Type, From 2016-2021 (USD Billion)
  15. South Korea Multiple Myeloma Therapeutics Market By Drug Type, From 2016-2021 (USD Billion)
  16. Australia Multiple Myeloma Therapeutics Market By Treatment Type, From 2016-2021 (USD Billion)
  17. Australia Multiple Myeloma Therapeutics Market By Drug Type, From 2016-2021 (USD Billion)
  18. Asia-Pacific Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  19. Asia-Pacific Anthracycline Antibiotic Market By Region, From 2016-2021 (USD Billion)
  20. Asia-Pacific Alkylating Agent Market By Region, From 2016-2021 (USD Billion)
  21. China Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  22. India Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  23. Japan Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  24. South Korea Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  25. Australia Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  26. Asia-Pacific Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  27. Asia-Pacific Melphalan (Alkeran) Market By Region, From 2016-2021 (USD Billion)
  28. Asia-Pacific Liposomal doxorubicin (Doxil) Market By Region, From 2016-2021 (USD Billion)
  29. China Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  30. India Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  31. Japan Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  32. South Korea Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  33. Australia Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  34. Asia-Pacific Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  35. Asia-Pacific Doxorubicin (Adriamycin) Market By Region, From 2016-2021 (USD Billion)
  36. Asia-Pacific Cyclophosphamide (Neosar) Market By Region, From 2016-2021 (USD Billion)
  37. Asia-Pacific Vincristine (Oncovin) Market By Region, From 2016-2021 (USD Billion)
  38. Asia-Pacific Carmustine (BiCNU) Market By Region, From 2016-2021 (USD Billion)
  39. China Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  40. India Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  41. Japan Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  42. South Korea Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  43. Australia Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2016-2021 (USD Billion)
  44. Asia-Pacific Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2016-2021 (USD Billion)
  45. Asia-Pacific Bortezomib (Velcade) Market By Region, From 2016-2021 (USD Billion)
  46. Asia-Pacific Carfilzomib (Kyprolis) Market By Region, From 2016-2021 (USD Billion)
  47. China Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2016-2021 (USD Billion)
  48. India Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2016-2021 (USD Billion)
  49. Japan Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2016-2021 (USD Billion)
  50. South Korea Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2016-2021 (USD Billion)
  51. Australia Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2016-2021 (USD Billion)
  52. Asia-Pacific Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2016-2021 (USD Billion)
  53. Asia-Pacific Dexamethasone (Decadron) Market By Region, From 2016-2021 (USD Billion)
  54. Asia-Pacific Prednisone (Deltasone/Orasone) Market By Region, From 2016-2021 (USD Billion)
  55. China Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2016-2021 (USD Billion)
  56. India Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2016-2021 (USD Billion)
  57. Japan Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2016-2021 (USD Billion)
  58. South Korea Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2016-2021 (USD Billion)
  59. Australia Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2016-2021 (USD Billion)
  60. Asia-Pacific Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2016-2021 (USD Billion)
  61. Asia-Pacific Thalidomide (Thalomid) Market By Region, From 2016-2021 (USD Billion)
  62. Asia-Pacific Lenalidomide (Revlimid) Market By Region, From 2016-2021 (USD Billion)
  63. Asia-Pacific Arsenic trioxide (Trisenox) Market By Region, From 2016-2021 (USD Billion)
  64. Asia-Pacific Plerixafor (Mozobil) Market By Region, From 2016-2021 (USD Billion)
  65. China Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2016-2021 (USD Billion)
  66. India Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2016-2021 (USD Billion)
  67. Japan Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2016-2021 (USD Billion)
  68. South Korea Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2016-2021 (USD Billion)
  69. Australia Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2016-2021 (USD Billion)
Middle East And Africa Non-Surgical Skin Tightening Market By Product (Laser-based Devices, RF Devices, Ultrasound Devices, And Other Devices), End User (Dermatology Clinics, And Beauty Clinics), And Region - Indust...
Latin America Non-Surgical Skin Tightening Market By Product (Laser-based Devices, RF Devices, Ultrasound Devices, And Other Devices), End User (Dermatology Clinics, And Beauty Clinics), And Region - Industry Analys...
Asia Pacific Non-Surgical Skin Tightening Market By Product (Laser-based Devices, RF Devices, Ultrasound Devices, And Other Devices), End User (Dermatology Clinics, And Beauty Clinics), And Region - Industry Analysi...
North America Non-Surgical Skin Tightening Market By Product (Laser-based Devices, RF Devices, Ultrasound Devices, And Other Devices), End User (Dermatology Clinics, And Beauty Clinics), And Region - Industry Analys...
Non-Surgical Skin Tightening Market By Product (Laser-based Devices, RF Devices, Ultrasound Devices, And Other Devices), End User (Dermatology Clinics, And Beauty Clinics), And Region - Global Industry Analysis, Siz...
Middle East And Africa Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Industry Analysis...
Latin America Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Industry Analysis, Size, S...
Asia Pacific Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Industry Analysis, Size, Sh...
Europe Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Industry Analysis, Size, Share, G...
North America Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Industry Analysis, Size, S...
Pigmented Lesion Treatment Market By Product (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), End User (Beauty Clinics, Dermatology Clinics), And Region - Global Industry Analysis, Size, Share, G...
Middle East And Africa Dermal Fillers Market By Product (Absorbable Or Biodegradable, Non-Absorbable Or Non-Biodegradable), Therapeutic Area (Wrinkles, Deep Facial Lines, Sagging Skin, Scars), And Region -Industry A...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.